Neumora Therapeutics (NMRA) Accounts Payables (2022 - 2026)

Neumora Therapeutics has reported Accounts Payables for 5 years, with the latest figure at $5.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 380.7% year-over-year to $5.1 million; the trailing twelve-month figure through Mar 2026 stood at $5.1 million (up 380.7% YoY), and the FY2025 full-year result was $3.4 million, up 2.18% from the prior year.
• Accounts Payables for Q1 2026 stood at $5.1 million, up from $3.4 million in the prior quarter.
• The five-year high for Accounts Payables was $7.1 million in Q4 2022, with the low at $337000.0 in Q4 2023.
• Average Accounts Payables over 5 years is $2.7 million, with a median of $1.9 million recorded in 2023.
• Year-over-year, Accounts Payables tumbled 95.28% in 2023 and surged 881.31% in 2024.
• Tracing NMRA's Accounts Payables over 5 years: stood at $7.1 million in 2022, then plunged by 95.28% to $337000.0 in 2023, then surged by 881.31% to $3.3 million in 2024, then grew by 2.18% to $3.4 million in 2025, then soared by 49.66% to $5.1 million in 2026.
• The last three Accounts Payables figures came in at $5.1 million (Q1 2026), $3.4 million (Q4 2025), and $549000.0 (Q3 2025), per Business Quant data.

Peer Comparison